Crotalus Snake Venom Preconditioning to Prevent Surgical Brain Injury by Kim, Cherine Hee-Sun
Loma Linda University
TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Loma Linda University Electronic Theses, Dissertations & Projects
6-2015
Crotalus Snake Venom Preconditioning to Prevent
Surgical Brain Injury
Cherine Hee-Sun Kim
Follow this and additional works at: http://scholarsrepository.llu.edu/etd
Part of the Biochemistry Commons, and the Medical Biochemistry Commons
This Dissertation is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative
Works. It has been accepted for inclusion in Loma Linda University Electronic Theses, Dissertations & Projects by an authorized administrator of
TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works. For more information, please contact
scholarsrepository@llu.edu.
Recommended Citation
Kim, Cherine Hee-Sun, "Crotalus Snake Venom Preconditioning to Prevent Surgical Brain Injury" (2015). Loma Linda University
Electronic Theses, Dissertations & Projects. 224.
http://scholarsrepository.llu.edu/etd/224
	   
 
 
 
LOMA LINDA UNIVERSITY 
School of Medicine 
in conjunction with the 
Faculty of Graduate Studies 
 
 
 
____________________ 
 
 
 
 
Crotalus Snake Venom Preconditioning to Prevent Surgical Brain Injury 
 
 
by 
 
 
Cherine Hee-Sun Kim 
 
 
 
____________________ 
 
 
 
 
A Dissertation submitted in partial satisfaction of 
the requirements for the degree 
Doctor of Philosophy in Biochemistry 
 
 
 
____________________ 
 
 
 
 
June 2015 
 
 
 
	   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 
 
Cherine Kim 
All Rights Reserved 
iii 
Each person whose signature appears below certifies that this dissertation in 
his/her opinion is adequate, in scope and quality, as a dissertation for the degree 
Doctor of Philosophy. 
 
 
 
 
 
 
 , Chairperson 
John H. Zhang. Professor of Basic Sciences, Neurosurgery, Neurology, 
Anesthesiology, Physiology  
 
 
 
 
  
Penelope Duerksen-Hughes, Professor of Basic Sciences 
 
 
 
 
  
Helen Huang, Assistant Research Professor of Anesthesiology and Basic 
Sciences 
 
 
 
 
  
Andre Obenaus, Associate Professor of Pediatrics and Basic Sciences 
 
 
 
 
  
Jiping Tang, Professor of Basic Sciences 
 
 
 
 
  
iv 
ACKNOWLEDGEMENTS 
 
 
 I cannot express enough gratitude to Dr. John H. Zhang for his support, 
patience, and dedication to my training. Through a careful balance between 
offering meticulous guidance and allowing creative autonomy, he has provided 
me limitless opportunities. Through him, I have witnessed that there are no 
boundaries to the marvels of science and research. Thank you so much, Dr. 
Zhang. I hope that you can be proud of the scientist that you have molded. 
 I would also like to thank my committee members, who have offered 
tremendous support and knowledge throughout my training. To Dr. Duerksen-
Hughes, thank you for your constant encouragement. You helped me navigate 
through the most difficult times of my training and for that I will be forever 
grateful. Dr. Huang, I want to thank you for challenging us to improve our study 
designs and surgical model. To Dr. Obenaus, thank you for your insight, support, 
and continued collaboration with our laboratory. Dr. Jiping Tang, I want to thank 
you for your advice and support and for exemplifying the type of educator that I 
hope to become. 
To my family and friends, I could not have done this without your love and 
support. I want to thank my grandparents and parents for the sacrifices they have 
made to ensure that I had every opportunity and advantage for success. 
Grandma, thank you for your selfless, unconditional love and for teaching me 
about life, love, and family. Grandpa, you are the true scholar in our family; thank 
you for inspiring me to pursue academics. Mom, you have always been my 
source of strength and resilience—thank you for everything. To my Dad, thank 
v 
you for sharing your love for math and science with me when I was a little girl and 
thank you for the nerdy humor that has given me a joyful perspective of working 
in science. To my brother Justin, thank you for keeping me grounded and for 
editing every important essay or manuscript I have ever written. To my dearest 
Euntaik, thank you so very much for your love and patience, and for respecting 
my career choices. And finally, I would like to thank God, for leading me down 
this extraordinary path—a journey that has far surpassed my own hopes and 
dreams. 
vi 
CONTENTS 
 
 
Approval Page ....................................................................................................... iii 
 
Acknowledgements .............................................................................................. iv 
 
Table of Contents ................................................................................................. vi 
 
List of Figures ....................................................................................................... ix 
 
List of Tables ......................................................................................................... x 
 
List of Abbreviations ............................................................................................. xi 
 
Abstract ................................................................................................................ xii 
 
Chapter 
 
1. Introduction to Surgical Brain Injury and Neuroprotective 
Preconditioning Therapies .......................................................................... 1 
 
Surgical Brain Injury .............................................................................. 2 
Surgical Brain Injury Rodent Model ....................................................... 3 
Pathophysiology of Surgical Brain Injury ............................................... 6 
 
Brain Edema .................................................................................... 6 
Cell Death ........................................................................................ 8 
Perioperative Hemorrhage ............................................................... 8 
 
Neuroprotective Preconditioning Therapies .......................................... 9 
 
Hyperbaric Oxygen ........................................................................ 11 
Inhalatory Anesthetics ................................................................... 14 
N-Methyl-D-Aspartate .................................................................... 16 
 
Future Directions ................................................................................. 20 
References .......................................................................................... 21 
 
2. Crotalus Snake Venom: Potential for Preconditioning in Surgical 
Brain Injury  ............................................................................................... 27 
 
Therapeutic Uses of Venoms .............................................................. 27 
Crotalus Snakes and Venom .............................................................. 28 
Crotalus Venom as a Potential Preconditioning Agent for 
Reducing Postoperative Inflammation in Surgical Brain Injury ........... 29 
vii 
Crotalus Venom as a Potential Preconditioning Agent for 
Reducing Perioperative Hemorrhage in Surgical Brain Injury ............. 29 
Research Questions, Hypotheses, and Specific Aims ........................ 31 
References .......................................................................................... 35 
 
3. Crotalus Snake Venom Preconditioning Reduces Postoperative 
Brain Edema and Improves Neurological Outcomes After Surgical 
Brain Injury ................................................................................................ 39 
 
Introduction.......................................................................................... 39 
Results ................................................................................................ 40 
 
Cv-PC Reduces Brain Water Content after SBI ............................ 40 
Cv-PC Improves Neurological Function after SBI .......................... 41 
COX-2 Inhibition Reverses Cv-PC Effects on Brain Water 
Content and Neurological Function after SBI ................................ 43 
Cv-PC Reduces Expression of Inflammatory Mediators 
COX-2 and PGE2 in SBI ................................................................. 43 
 
Discussion ........................................................................................... 47 
Material and Methods .......................................................................... 48 
 
Animal Experiments ....................................................................... 48 
Neurological Testing ...................................................................... 48 
Brain Water Content ...................................................................... 49 
Western Blot .................................................................................. 49 
Immunohistochemistry ................................................................... 50 
Statistical Analysis ......................................................................... 50 
Study Approval .............................................................................. 51 
 
Acknowledgements ............................................................................. 51 
References .......................................................................................... 52 
 
4. Crotalus Atrox Venom Preconditioning Increases Plasma 
Fibrinogen and Reduces Perioperative Hemorrhage in Surgical 
Brain Injury Rats ....................................................................................... 54 
 
Introduction.......................................................................................... 54 
Results ................................................................................................ 56 
 
Cv-PC Reduces Intraoperative Blood Loss In Vivo ....................... 56 
Cv-PC Reduces Postoperative Hematoma In Vivo ....................... 56 
Cv-PC increases Plasma Fibrinogen and Plasma Fibrin Split 
Products In Vivo ............................................................................. 59 
PT, INR, PTT, D-Dimer, and Soluble Fibrin Remain Normal 
After Cv-PC .................................................................................... 59 
viii 
PC with Several Cv Fractions Reduces Intraoperative 
Hemorrhage and Postoperative Hematoma Volumes In Vivo ....... 62 
MMP Inhibition Blocks Cv-PC Effects on Hemorrhage 
Volumes, Plasma Fibrinogen, and Fibrin Split Products ................ 62 
Direct Fibrinogen Administration Reduces Intraoperative 
Hemorrhage and Postoperative Hematoma Volumes In Vivo ....... 65 
Crotalus Atrox Venom Causes Dose-dependent Hemostatic 
Changes in Human Whole Blood In Vitro ...................................... 65 
 
Discussion ........................................................................................... 67 
 
Choice of Crotalus Venom ............................................................. 67 
Effects of Cv on Coagulation ......................................................... 68 
Identifying the Role of SVMP in PC Against SBI ........................... 69 
Investigation of the Role of Fibrinogen in Cv-PC ........................... 70 
Clotting, Clumping, and Sticking Tests .......................................... 70 
Clinical Application of Increasing Plasma Fibrinogen Levels 
Before Major Elective Surgery ....................................................... 71 
 
Material and Methods .......................................................................... 73 
 
Animal Experiments ....................................................................... 73 
Spectrophotometric Assay of Hemoglobin ..................................... 74 
Blood Draws ................................................................................... 75 
Soluble Fibrin Analysis .................................................................. 76 
PT, INR, PTT, Fibrinogen Analysis ................................................ 76 
D-Dimer Analysis ........................................................................... 76 
Fibrin Split Products Analysis ........................................................ 77 
HPLC ............................................................................................. 77 
LC-MS ............................................................................................ 78 
Gel Filtration Chromatography ....................................................... 79 
Minimal Stimulation In Vitro Clotting/Platelet Testing .................... 79 
Statistical Analysis ......................................................................... 81 
Study Approval .............................................................................. 81 
 
Acknowledgements ............................................................................. 81 
References .......................................................................................... 82 
 
5. Conclusions .............................................................................................. 88 
 
Summary of Findings .......................................................................... 88 
Clinical Implications ............................................................................. 89 
References .......................................................................................... 90 
 
  
ix 
FIGURES 
 
 
Figures Page 
 
1.1 Partial Right Frontal Lobectomy ............................................................ 5 
1.2 Proposed Scheme for Surgical Brain Injury Pathophysiology and 
Potential Preconditioning Interventions ............................................... 13 
1.3 Proposed Mechanism of NMDA Preconditioning on Surgical 
Brain Injury .......................................................................................... 19 
2.1 Schematic of Specific Aims ................................................................. 34 
3.1 Cv-PC Reduces Brain Edema and Improves Neurological 
Function in SBI .................................................................................... 42 
3.2 COX-2 Inhibition Reverses Cv-PC Effects .......................................... 44 
3.3 COX-2 Western Blot Analysis ............................................................. 45 
3.4 Immunohistological Staining of Ipsilateral Frontal Lobe Tissue 
Near Resection Site Using Inflammatory Marker PGE2 ...................... 46 
4.1 Cv-PC Reduces Intraoperative Hemorrhage and Postoperative 
Hematoma in a Dose-dependent Manner in SBI ................................ 58 
4.2 Cv-PC Increases Plasma Fibrinogen and Generates Fibrin Split 
Products .............................................................................................. 60 
4.3 Reversed-Phase HPLC and Gel Filtration Chromatographs of C. 
atrox Venom ........................................................................................ 63 
4.4 Cv-PC Intraoperative Hemorrhage and Postoperative 
Hematoma in SBI ................................................................................ 64 
4.5 Dose-dependent Efects of C. atrox Venom on Human Whole 
Blood In Vitro ....................................................................................... 66 
 
x 
TABLES 
 
Tables Page 
 
1.1 Experimental Animal Studies of Therapeutic Agents for Surgical 
Brain Injury ............................................................................................. 10 
4.1 Coagulation Parameters After Cv-PC .................................................... 61 
 
  
xi 
ABBREVIATIONS 
 
 
SBI    Surgical brain injury 
SVMP    Snake venom metalloproteinase 
PLA2    Phospholipase A2 
COX-2   Cyclooxygenase-2 
VEGF    Vascular endothelial growth factor 
ZO-1    Zona occludins-1 
BBB    Blood-brain barrier 
MMP    Matrix metalloproteinase 
HBO    Hyperbaric oxygen 
HBO-PC   Hyperbaric oxygen preconditioning 
ATA    Absolute atmosphere 
ROS    Reactive Oxygen Species 
HIF-1    Hypoxia-inducible factor-1a 
iNOS    Inducible NO synthase 
KATP    ATP-sensitive potassium channel 
CNS    Central nervous system 
NMDA   N-methyl-D-aspartate 
Cv    Crotalus venom 
PC    Preconditioning 
Cv-PC   Crotalus venom preconditioning 
PGE2    Prostaglandin E2 
xii 
ABSTRACT OF THE DISSERTATION 
Crotalus Snake Venom Preconditioning to Prevent Surgical Brain Injury 
 
by 
Cherine Hee-Sun Kim 
Doctor of Philosophy, Graduate Program in Biochemistry 
Loma Linda University, June 2015 
Dr. John H. Zhang, Chairperson 
 
Preventive measures are increasingly relevant to medical practice. 
Preconditioning, a preemptive therapy that administers mildly harmful stimuli to 
induce endogenous protective mechanisms before major injury, has been shown 
to minimize injury in many animal models. Given the elective nature of most 
neurosurgical procedures, the surgical brain injury (SBI) rodent model provides 
an ideal platform for preconditioning. Our work shows that preconditioning with 
Crotalus rattlesnake venom, known for its hemorrhagic and inflammatory effects, 
mitigates some harmful effects of SBI. We have identified two proteins of interest 
in Crotalus venom: snake venom metalloproteinase (SVMP), an enzyme with 
hemorrhagic effects, and phospholipase A2 (PLA2), an enzyme upstream to 
cyclooxygenase-2 (COX-2) in the inflammatory cascade. We have found that 
preconditioning Crotalus venom increases endogenous fibrinogen, decreases 
perioperative hemorrhage, attenuates COX-2 activity, and reduces postoperative 
brain edema. Further understanding of these enzymes may yield a novel, 
preventive approach to reducing perioperative hemorrhage and edema in 
elective neurosurgical procedures.
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CHAPTER ONE 
INTRODUCTION TO SURGICAL BRAIN INJURY AND NEUROPROTECTIVE 
PRECONDITIONING THERAPIES 
 
 
 
Adapted from 
 
 
Kim, C. H., Chen H., Zhang, J. H. (2013).  Preconditioning for surgical brain 
injury.  In Innate Tolerance in the CNS: Translational Neuroprotection by 
pro- and Post-Conditioning *(485-498).  New York, NY: Springer Science. 
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Surgical Brain Injury 
The delicate and complex architecture of the brain presents significant 
challenges for neurosurgery. Beneath the skull and meninges, the brain is highly 
susceptible to mechanical injury. Incision, retraction, and electrocauterization—all 
necessary neurosurgical maneuvers—can cause collateral damage to healthy 
tissue at the periphery of the operative site. Brain edema and hemorrhage are 
serious complications that commonly develop following neurosurgical procedures 
and may lead to further injury from hypoperfusion or cell death (Bruder and 
Ravussin 1999). Currently, surgical brain injury (SBI) is not specifically treated 
but is rather left to heal on its own. 
The complications of SBI may also hinder therapeutic approach. The 
current medical-legal climate has led to defensive medical practice by physicians 
in high-risk specialties. In a study published in the Journal of the American 
Medical Association, nearly 75% of polled neurosurgeons admitted to avoiding 
certain procedures or high-risk patients (Studdert, Mello et al. 2005). Diminishing 
perioperative risks could expand the possibility of more aggressive surgical 
interventions. In addition, with the rising costs of medical care, any measures to 
simplify perioperative care would be invaluable. Even neurosurgical patients 
without life-threatening complications must be monitored closely in the critical 
care unit. Thus, the benefits of limiting complications of SBI extend beyond 
improving morbidity and mortality. 
While preconditioning strategies have demonstrated promising 
neuroprotective effects for stroke and traumatic brain injury, they are of limited 
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clinical use because these injuries are not anticipated. In contrast, the predictable 
nature of SBI offers the opportunity to establish preemptive measures. To date, 
developing less invasive surgical methods has been the predominant strategy for 
limiting SBI, with relatively little research focused on understanding its 
biochemical pathophysiology. Thus, therapeutic strategies for SBI have yet to be 
adequately explored. In this chapter, we will describe SBI’s animal model, review 
its pathophysiology, and discuss potential preconditioning therapies for SBI. 
 
Surgical Brain Injury Rodent Model 
Despite its widespread impact and predictability, SBI is clinically 
addressed by rather nonspecific postoperative care. In order to facilitate the 
study of specific treatments for SBI, the in vivo model for SBI was recently 
developed by John H. Zhang and colleagues (Matchett, Hahn et al. 2006, 
Jadhav, Solaroglu et al. 2007, Yamaguchi, Jadhav et al. 2007). This rodent 
model was designed to mimic surgically induced brain injury. In brief, the rodent 
brain is exposed in a small window in the cranium through which tissue resection 
is performed. The margins of resection are delineated by distance from the 
bregma, as shown in Fig. 1.1. This partial right front lobectomy simulates the 
injuries sustained by neural tissue from standard neurosurgical maneuvers. The 
model provides for a consistently measureable edema by brain water content in 
perilesional tissue and neurological deficits following SBI. The model mimics 
injuries characteristic of general neurosurgical procedures, producing 
reproducible brain tissue loss and injury that is representative of routine 
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neurosurgeries in clinical practice and provides a platform from which to study 
the molecular mechanisms involved in SBI pathophysiology as well as potential 
therapeutic agent. 
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Figure 1.1 Partial right frontal lobectomy. Two incisions (interrupted lines) are 
made leading away from the bregma (white ×) along the sagittal and coronal 
planes 2 mm lateral and 1 mm proximal to the sagittal and coronal sutures, 
respectively. 
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Pathophysiology of Surgical Brain Injury 
Surgical brain injury is caused by both primary and secondary injury 
mechanisms. Primary injury, inflicted directly by mechanical forces at the time of 
injury, is largely inescapable and irreversible. Secondary injury entails a cascade 
of cellular and metabolic disruption triggered by the primary insult. Typical 
biochemical disturbances of secondary injury involve the generation of toxic and 
inflammatory molecules, such as reactive oxygen species, prostaglandins, and 
cytokines. The principal complications that result from such mechanisms after 
SBI are brain edema, cell death, and hemorrhage. 
 
Brain Edema 
Localized brain edema has been shown to be a major postoperative 
complication of SBI. Many rodent studies indicate that the brain water content of 
tissue surrounding the resection site is increased by approximately 3% during the 
first three postoperative days and gradually resolves by a week after surgery 
(Matchett, Hahn et al. 2006, Yamaguchi, Jadhav et al. 2007). This sequence was 
further supported with measured apparent diffusion coefficients by magnetic 
resonance imaging (Matchett, Hahn et al. 2006). Brain edema is believed to 
develop from both vasogenic and cytotoxic mechanisms. In vasogenic edema 
formation, loss of blood-brain barrier (BBB) integrity causes extravasation of 
proteins from the vascular compartment and subsequent fluid accumulation in 
brain tissue. Cytotoxic edema is formed by fluid accumulation in cells from 
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improper ion balance. Brain edema is followed by increased intracranial 
pressure, which may lead to local ischemia, herniation, and cell death. 
SBI leads to abnormal extravasation of proteins from the vasculature, 
suggesting loss of BBB integrity (Matchett, Hahn et al. 2006, Jadhav, Solaroglu 
et al. 2007, Bravo, Matchett et al. 2008, Di, Yan-Ting et al. 2008, Jadhav, 
Yamaguchi et al. 2008, Lee, Jadhav et al. 2008, Hao, Wu et al. 2009). While a 
clear mechanism for SBI-induced BBB disruption has yet to emerge, growth 
factors and inflammatory pathways have been implicated in previous studies. SBI 
is characterized by increased expression of vascular endothelial growth factor 
(VEGF) and decreased expression of zona occludens-1 (ZO-1), a tight junction 
protein; inhibition of ERK1/2 phosphorylation suppresses VEGF expression and 
salvages ZO-1 expression (Jadhav, Matchett et al. 2007). Another growth factor, 
erythropoietin, exacerbates brain edema in SBI (Matchett, Hahn et al. 2006). 
Other studies have shown increased extracellular matrix degradation by matrix 
metalloproteinases (MMPs) in SBI, compromising the basement membrane of 
endothelial cells (Yamaguchi, Jadhav et al. 2007). A key enzyme in the 
production of prostaglandins and other inflammatory mediators, cyclooxygenase-
2 (COX-2) appears to play a role in the induction of brain edema in SBI as well 
(Jadhav, Ostrowski et al. 2009, Jadhav, Ostrowski et al. 2010). Lipid peroxidation 
by reactive oxygen species (ROS) has been implicated in BBB disruption (Lo, 
Bravo et al. 2007, Lee, Jadhav et al. 2008, Lee, Jadhav et al. 2009). 
Inflammatory mediators are notorious participants in BBB regulation, yet they 
alone do not dictate the development of edema following SBI. Hyong et al. 
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demonstrated the capacity of rosiglitazone to decrease inflammatory markers, 
such as tumor necrosis factor-a, interleukin-b, and myeloperoxidase, following 
SBI; however, brain edema and BBB disruption persisted (Hyong, Jadhav et al. 
2008). 
 
Cell Death 
Apoptosis and other forms of cell death have also been implicated in SBI. 
Several studies have reported apoptotic changes at the perilesional site in SBI 
(Matchett et al. 2006; Bravo et al. 2008; Sulejczak et al. 2008). Matchett et al. 
demonstrated apoptotic neuronal death by positive triple immunostaining for 
terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling, cleaved 
caspase 3, and NeuN (Matchett, Hahn et al. 2006). Neuronal apoptosis was later 
shown to be accompanied by astrogliosis in the perilesional area (Sulejczak, 
Grieb et al. 2008). 
 
Perioperative Hemorrhage 
Hemorrhage is a major obstacle in neurosurgery and likely contributor to 
SBI. Postoperative hemorrhage in SBI may trigger injury by disrupting the BBB 
by similar mechanisms as observed in the intracerebral hemorrhage and 
subarachnoid hemorrhage stroke models. Intraoperative bleeding can obscure 
the surgical field and cause local ischemic insult, as well as systemic 
cardiovascular and respiratory instability. Extensive losses may require blood 
transfusions, prolonging the surgery. Procedure duration, extended by efforts to 
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stem bleeding, is itself a risk. Achieving hemostasis is unquestionably critical in 
all types of surgeries but poses unique challenges in neurosurgery. Many 
surgical methods for controlling bleeding, such as clamping or suturing, are 
unacceptable in neurosurgery because of the delicate nature of brain tissue. 
Since Harvey Cushing first introduced its surgical use in 1928, 
electrocauterization has been the primary neurosurgical method of reducing 
intraoperative bleeding (Voorhees, Cohen-Gadol et al. 2005). While a 
groundbreaking addition to neurosurgery, electrocauterization itself can cause 
the destruction of healthy brain tissue either directly or by thermal injury. 
 
Neuroprotective Preconditioning Therapies 
Currently, clinical management of surgical brain injury is limited to 
nonspecific postoperative care. Many promising therapeutic agents and 
strategies to mitigate complications of SBI have been observed in animal models 
(summarized in Table 1.1); however, nearly all of these studies utilized pre- or 
post-treatments. SBI presents a unique opportunity to test neuroprotection by 
preconditioning therapies that may prove clinically relevant. In the following text, 
we propose the use of hyperbaric oxygen, inhalatory anesthetic, and N-methyl-D-
aspartate as preconditioning agents for SBI.  
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Table 1.1. Experimental animal studies of therapeutic agents for surgical brain 
injury. 
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Hyperbaric Oxygen 
To date, hyperbaric oxygen (HBO) is the only preconditioning therapy that 
has been successful in the surgical brain injury model. Jadhav et al. investigated 
brain edema and neurological outcome with HBO preconditioning (HBO-PC) 
treatment in mice subjected to SBI (Jadhav, Ostrowski et al. 2009, Jadhav, 
Ostrowski et al. 2010). The mice were treated with 100% for 1 h at 2.5 absolute 
atmosphere (ATA) for five consecutive days prior to surgery. Examined at 24 h 
and 72 h after surgery, the HBO-treated mice subjected to SBI showed both 
decreased brain water content and improved neurological status, which was 
assessed by 21-point sensorimotor scoring and wire-hang and beam-balance 
tests. The authors suggested that the benefits of HBO-PC for SBI are mediated 
by COX-2, as its inhibition reversed the effects, and SBI-induced COX-2 
overexpression was attenuated by HBO-PC.  
HBO preconditioning has demonstrated neuroprotective effects in several 
models of stroke and brain injury; however, its mechanism is not fully 
understood. Most studies have shown that the key benefit of HBO-PC is 
apoptosis inhibition. Ostrowski et al. suggested that HBO-PC reduced the 
activation of the p38 apoptotic pathway and upregulated the expression of 
neurotrophins, such as brain-derived neurotrophic factor (Ostrowski, Graupner et 
al. 2008). Hypoxia-inducible factor-1alpha (HIF-1) has also been implicated as a 
mediator of HBO-PC. A transcription factor expressed in response to hypoxia, 
HIF-1 governs genes responsible for adaptive responses (Carmeliet, Dor et al. 
1998); however, the actions of HIF-1 are complex, as excessive accumulation of 
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HIF-1 results in the activation of proapoptotic and proinflammatory pathways 
(Halterman, Miller et al. 1999, Li, Zhou et al. 2005). Jadhav et al. observed 
increased HIF-1a expression following SBI that was reduced by 5 days of HBO-
PC at 2.5 ATA (Jadhav, Ostrowski et al. 2009). In contrast, Peng et al. 
demonstrated that the same HBO-PC treatment upregulated HIF-1a expression 
in a mouse hypoxia model (Peng, Ren et al. 2008). In short, HIF-1a needs more 
experimental study to clarify its role in HBO-PC.  
HBO-PC has also been shown to activate endogenous antioxidants. HBO 
appears to present an oxidative challenge to which the brain upregulates the 
activity of endogenous antioxidants, such as superoxide dismutase, in global 
ischemia models (Wada, Miyazawa et al. 2001, Nie, Xiong et al. 2006). The 
induction of antioxidant systems prior to injury would bolster the ability to limit 
oxidative damage and cell membrane disruption by ROS following brain insult, 
preserving BBB integrity (Fig. 1.2).  
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Figure 1.2 Proposed scheme of surgical brain injury pathophysiology and 
potential preconditioning interventions. HBO hyperbaric oxygen, PC 
preconditioning, COX-2 cyclooxygenase-2, MPO myeloperoxidase, ROS reactive 
oxygen species. 
  
492 C.H. Kim et al.
Research studies and clinical trials have quelled fears of toxicity and established that 
HBO treatment pressure at 1.5 ATA is well tolerated without permanent pulmonary 
complications (Holbach et al.  1972,  1977 ; Rockswold et al.  1992,  2007 ) . The vari-
ability in HBO-PC dosing regimen presents another challenge; studies have differed 
in exposure pressure, timing, number, and duration of sessions. This complicates the 
translation of HBO-PC into the clinic. Thus, the challenges of introducing HBO-PC 
as an acceptable therapy for SBI are to establish ef fi cacy and safety of treatment. 
 22.4.2  Inhalatory Anesthetics 
 Preconditioning with inhalatory anesthetics has shown some promising neuroprotec-
tive results in experimental stroke models—studies have shown reduction of infarct 
volumes and improvement of neurological de fi cit scores in cerebral ischemia (Zhao 
and Zuo  2004 ; Zheng and Zuo  2004 ; Payne et al.  2005 ; Liu et al.  2006 ; Kapinya et al. 
 2002 ) . Some studies have suggested the induction of nitric oxide synthase as a potential 
mechanism for inhalatory anesthetic preconditioning. Kapinya et al. demonstrated the 
 Fig. 22.2  Prop sed cheme of surgical brain injury pathophysiology and potential precondition-
ing interventions.  HBO hyperbaric oxygen,  PC preconditioning,  COX-2 cyclooxygenase-2,  MPO 
myeloperoxidase,  ROS reactive oxygen species 
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Historically, the clinical use of HBO-PC has been controversial because of 
oxygen toxicity issues. HBO generated oxidative stress on vulnerable tissues, 
such as the lung, is a valid concern; however, the hazards of HBO may be 
somewhat overstated. Research studies and clinical trials have quelled fears of 
toxicity and established that HBO treatment pressure at 1.5 ATA is well tolerated 
without permanent pulmonary complications (Holbach, Schroder et al. 1972, 
Holbach, Caroli et al. 1977, Rockswold, Ford et al. 1992, Rockswold, Rockswold 
et al. 2007). The variability in HBO-PC dosing regimen presents another 
challenge; studies have differed in exposure pressure, timing, number, and 
duration of sessions. This complicates the translation of HBO-PC into the clinic. 
Thus, the challenges of introducing HBO-PC as an acceptable therapy for SBI 
are to establish efficacy and safety of treatment.  
 
Inhalatory Anesthetics 
Preconditioning with inhalatory anesthetics has shown some promising 
neuroprotective results in experimental stroke models—studies have shown 
reduction of infarct volumes and improvement of neurological deficit scores in 
cerebral ischemia (Kapinya, Lowl et al. 2002, Zhao and Zuo 2004, Zheng and 
Zuo 2004, Payne, Akca et al. 2005, Liu, Xiong et al. 2006). Some studies have 
suggested the induction of nitric oxide synthase as a potential mechanism for 
inhalatory anesthetic preconditioning. Kapinya et al. demonstrated the increase 
of inducible NO synthase (iNOS) from inhalatory anesthetic preconditioning in an 
ischemic model; the reduction of infarct was eliminated with the administration of 
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an iNOS inhibitor (Kapinya, Lowl et al. 2002). Another study by Zhao and Zuo 
showed analogous results in a neonatal hypoxia-ischemia model (Zhao and Zuo 
2004). KATP channels in the brain, especially those of mitochondrial origin, 
appear to play a major role in reducing neuronal death from brain injury. 
Preconditioning with inhalatory anesthetics is thought to be neuroprotective 
through KATP channel opening and activation; the inhibition of KATP channels 
has been shown to abolish the beneficial effects of inhalatory anesthetic 
preconditioning in both in vitro and in vivo studies (Xiong, Zheng et al. 2003, 
Kehl, Payne et al. 2004, Kaneko, Yokoyama et al. 2005). Adenosine A1 receptor 
activation has been suggested to be a trigger for KATP channel opening in 
inhalatory anesthetic preconditioning (Liu, Xiong et al. 2006); however, 
downstream effects of KATP channel opening that mediate neuroprotection are 
not well understood. Studies investigating the action of inhalatory anesthetic 
preconditioning of cardiac tissue have demonstrated improved mitochondrial 
energy generation and increased ROS production that was dependent on 
mitochondrial KATP channel opening (Tanaka, Weihrauch et al. 2003, O'Rourke 
2004) (O’Rourke 2004; Tanaka et al. 2003). Thus, KATP channel-mediated 
neuroprotection seen in inhalatory anesthetic preconditioning may also be 
mediated by ROS production, a pathway shared by other therapies, such as 
HBO-PC or ischemic preconditioning. More research is needed to establish 
downstream effects of KATP channel activation in brain.  
Most preconditioning studies have utilized isoflurane because of its 
availability and limited systemic side effects. The few studies that have studied 
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the neuroprotective effects of halothane preconditioning have shown conflicting 
results in rodent cerebral ischemia models. Some have suggested that halothane 
may offer a therapeutic window of neuroprotection (Baughman, Hoffman et al. 
1988, Warner, McFarlane et al. 1993, Warner, Ludwig et al. 1995, Sarraf-Yazdi, 
Sheng et al. 1999); however, the argument for its clinical relevance is a moot 
point, as halothane is no longer manufactured in the United States because of its 
potential hepatotoxicity (Kitano, Kirsch et al. 2007). Sevoflurane has recently 
been utilized for preconditioning studies and has shown encouraging results in 
hypoxia-ischemia models (Kehl, Payne et al. 2004, Payne, Akca et al. 2005). 
Xenon has also emerged as promising preconditioning agent for neuroprotection 
(Bantel, Maze et al. 2009, Limatola, Ward et al. 2010).  
The potential induction of ROS by inhalatory anesthetic preconditioning is 
of particular interest for the treatment of SBI. HBO-PC has demonstrated ROS 
ability to activate endogenous antioxidant systems. Inhalatory anesthetics offer a 
potentially less hazardous and more convenient way to precondition by oxidative 
challenge (Fig. 1.2). Further studies are needed to examine the effects of 
inhalatory anesthetic preconditioning on cerebral edema and BBB integrity.  
 
N-Methyl-D-Aspartate 
Glutamate is a major excitatory neurotransmitter of the central nervous 
system (CNS) that is involved in the pathophysiology of brain injuries. Glutamate 
concentrations have been reported to rise significantly following various types of 
CNS injury, such as ischemia or trauma (Benveniste, Drejer et al. 1984, 
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Katayama, Tamura et al. 1991, Liu, Thangnipon et al. 1991). Excessive 
activation of ionotropic N-methyl-D-aspartate (NMDA) receptors by glutamate in 
the postsynaptic cell causes an influx of sodium and calcium that overwhelms the 
cell’s ability to maintain the ion hemostasis. The accumulation of intracellular 
sodium may result in cellular edema, while intracellular calcium can cause the 
inappropriate activation of regulatory cascades that mediate cell death (Choi, 
Maulucci-Gedde et al. 1987, Choi 1994, Choi 1995). In addition, glutamate-
induced over-activation of the CNS augments the metabolic needs of neural 
tissue.  
In vitro studies have shown NMDA-PC to protect cultured neurons from 
subsequently administration of a neurotoxic concentration of glutamate (Chuang, 
Gao et al. 1992). Calcium involvement in NMDA-PC was confirmed by Raval and 
colleagues (Raval, Dave et al. 2003). Their in vitro study demonstrated that 
calcium chelation abolished the neuroprotective effects of NMDA-PC. NMDA 
preconditioning has been shown to reduce neuronal death from not only 
excitotoxic damage but from oxidative insults as well (Smith, Stone et al. 2008). 
Most in vivo NMDA-PC studies have focused on investigating its anticonvulsant 
effects; however, one has examined its efficacy in traumatic brain injury. In a 
2010 study, Costa et al. observed that NMDA-PC improved neurological function 
in the mouse traumatic brain injury model (Costa, Constantino et al. 2010).  
Though its clinical applicability has yet to be established, NMDA-PC has 
shown promising results in both in vitro and in vivo models of ischemia and CNS 
injury. The importance of glutamate-induced excitotoxicity in the 
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pathophysiological sequelae of SBI is yet unknown; however, glutamate’s role in 
other similar insults, like traumatic brain or spinal cord injury, suggests that 
limiting glutamate signaling may prove beneficial in SBI as well. NMDA-PC could 
theoretically limit apoptosis and brain edema of SBI by a mechanism similar to 
that has been observed in ischemia and traumatic brain injury (Fig. 22.3). The 
ability of NMDA-PC to protect against neuronal death could prove clinically useful 
in limiting the complications of SBI.  
  
	  19 
 
 
 
 
 
 
 
Figure 1.3. Proposed mechanism of NMDA preconditioning on surgical brain 
injury. NMDA preconditioning (NMDA-PC) attenuates glutamate over-activation, 
reducing cell edema and death. NMDA-R NMDA receptor, SBI surgical brain 
injury 
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Future Directions 
The anticipatable timing of surgical brain injury provides a unique 
opportunity for preemptive intervention, but clinical medicine has yet to utilize 
preconditioning methods to protect the brain from SBI. Before these therapies 
can be tested by clinical trial, further in vivo experimental studies are needed to 
evaluate preconditioning agents and to provide a better mechanistic 
understanding of SBI pathophysiology. The pathophysiological understanding of 
SBI is still sparse compared that of other stroke or brain injury models. To date, 
SBI studies have implicated certain potential pathways, such as the p38 
apoptotic and the COX-2-mediated inflammatory pathways. Further studies are 
needed to expand on upstream and downstream mediators of these signaling 
pathways in the pathogenesis of SBI.  
HBO preconditioning has been shown to attenuate brain edema formation 
and neurological deterioration in surgical brain injury (Jadhav, Ostrowski et al. 
2009, Jadhav, Ostrowski et al. 2010). While HBO-PC has demonstrated 
promising results in animal studies, it remains to be seen whether it is feasible 
therapy in the clinical setting. A hyperbaric facility may not be easily accessible to 
neurosurgical patients, limiting the applicability of HBO-PC for SBI. In such a 
case, it would be important to examine other preconditioning therapies activating 
similar endogenous protective mechanisms.  
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CHAPTER TWO 
CROTALUS SNAKE VENOM: POTENTIAL FOR PRECONDITIONING IN 
SURGICAL BRAIN INJURY 
Therapeutic Uses of Venoms 
Recent advances in science recently have piqued interest in the use of 
snake venom in the medical field for their effects. Snake venoms are complex 
concoctions of deadly and pharmacologically active proteins. Scientists from 
various backgrounds have studied snake venoms to understand the mechanism 
of actions of its toxins either to find ways to neutralize the toxin effects during 
envenomation or to develop uses for the toxins in both research and clinical 
medicine.  
Snake venoms have long been studied for its effects on hemostasis. 
Snake venom toxins have been used to detect coagulative disorders in the 
medical laboratory (Marsh 2001), the anti-coagulative properties of snake venom 
have been studied for their potential in treating patients with hypercoagulative 
states, and the venoms with coagulative properties have been used to control 
bleeding (Earl, Masci et al. 2012). Others have been studied for potential 
antibacterial and anticancer properties (Nevalainen, Graham et al. 2008, 
Nascimento, Sancey et al. 2012, de Oliveira Junior, e Silva Cardoso et al. 2013). 
Only about 20% of snakes are venomous; the majority of these venom-producing 
snakes come from the families Elapidae, Viperidae, Colubridae, and 
Atractaspididae (Berling and Isbister 2015). 
 
	  28 
Crotalus Snakes and Venom 
There are more than 200 species of Viperidae; among these are the most 
dangerous snakes to human beings, including the rattlesnake subfamilies 
Crotalus and Sistrurus (Del Brutto and Del Brutto 2012). The venoms produced 
by the rattlesnakes in the Crotalus subfamily are recognized for their 
inflammatory and hemorrhagic effects. 
Crotalus helleri (formerly viridis), also known as the South Pacific 
rattlesnake, is a medium-sized snake that is responsible for the majority of 
snakebites in the coastal area of California (Wasserberger, Ordog et al. 2006, 
Sunagar, Undheim et al. 2014). Crotalus atrox, also known as the Western 
Diamondback rattlesnake, is the largest western rattlesnake in size in addition to 
being the most widely geographically spread monotypic rattlesnake species. 
Given its aggressive predisposition, C. atrox is the second highest cause of 
snakebite fatalities in the United States and the foremost cause in northern 
Mexico (Campbell and Lamar 2004).  
The venom of Crotalus snakes consists of hemorrhagic, hemotoxic, 
myotoxic, and cytotoxic components, along with some amounts of neurotoxins. 
Crotalus venoms are noted to contain PLA2 with myotoxic effects. Hemorrhagic 
components can lead to hemorrhage, myonecrosis, hypotension, hypovolemia, 
hemoconcentration, and shock (Campbell and Lamar 2004). C. atrox 
envenomation has been demonstrated to lead to persistent bleeding (Bjarnason 
and Tu 1978).  
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Crotalus Venom as a Potential Preconditioning Agent for Reducing 
Postoperative Inflammation in Surgical Brain Injury 
As previously discussed, COX-2, an enzyme downstream of PLA2, has been 
shown to mediate brain edema in SBI. COX-2 has also been identified as a 
potential mediator of HBO-PC in SBI—animals preconditioned for 1 hour daily for 
5 days with HBO prior to the induction of SBI had significantly improved 
neurological function and brain edema; with HBO-PC, COX-2 levels increased by 
2-fold in comparison to the 4-fold increase by the SBI, suggesting that protection 
conferred by HBO-PC involved increasing COX-2 to sub-injurious levels prior to 
SBI.  Furthermore, HBO-PC’s beneficial effects were reversed with the addition 
of selective COX-2 inhibitor to HBO-PC treatments (Jadhav, Ostrowski et al. 
2009, Jadhav, Ostrowski et al. 2010).  
 Crotalus snake venom is known to contain PLA2, an enzyme upstream to 
COX-2 in the inflammatory cascade, which converts membrane phospholipids 
into arachidonic acid (Bush and Siedenburg 1999, French, Hayes et al. 2004). 
Thus, Crotalus venom presents a new way to deliver sub-injurious increases in 
COX-2 levels in animals destined for SBI. 
 
 
Crotalus Venom as a Potential Preconditioning Agent for Reducing 
Perioperative Hemorrhage in Surgical Brain Injury 
Recent studies have highlighted low plasma fibrinogen levels as a key risk 
factor for perioperative hemorrhage during surgery (Gerlach, Tolle et al. 2002, 
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Ucar, Oc et al. 2007, Carling, Jeppsson et al. 2011, Adelmann, Klaus et al. 2014, 
Galas, de Almeida et al. 2014, Pillai, Fraser et al. 2014, Walden, Jeppsson et al. 
2014). These studies have demonstrated that lower plasma fibrinogen, even 
within normal limits, are associated with increased bleeding. Fibrinogen, an acute 
phase reactant with a half-life of 3.74 days (Martinez, Holburn et al. 1974), 
serves as the substrate for fibrin clot formation and circulates at the highest 
concentration of all the coagulation factors (Lowe, Rumley et al. 2004). Dilutional 
deficiency of fibrinogen develops before the development of any other hemostatic 
abnormality when plasma-poor red blood cell preparations are used to replace 
major blood loss (Hiippala, Myllyla et al. 1995). Yet the options for increasing 
plasma fibrinogen are limited to transfusions of fibrinogen-containing 
preparations such as fresh frozen plasma, cryoprecipitate, and fibrinogen 
concentrate. Fresh frozen plasma (FFP) varies in fibrinogen concentration as it is 
collected from donors and reportedly ranges between 100-300 mg/dL 
(Theusinger, Baulig et al. 2011). Cryoprecipitate, obtained by concentrating FFP, 
has a concentration of approximately 550 mg/dL (Lee, Lee et al. 2014). 
Fibrinogen concentrate, manufactured from human plasma and available as a 
pasteurized, lyophilized powder, is available at a concentration of 2000 mg/dL 
(Levy, Szlam et al. 2012). A previous study estimated that in order to raise 
plasma fibrinogen levels from 150 mg/dL to 170 mg/dL, 14 units of FFP, 8 units 
of cryoprecipitate, or 2 units of fibrinogen concentrate are required (Collins, 
Solomon et al. 2014); thus, fibrinogen supplementation by FPP and 
cryoprecipitate administration is limited by the possibility of causing fluid 
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overload. Additionally, these transfusions are associated with complications that 
include allergic reaction, infections, and transfusion-related acute lung injury 
(Busch, Glynn et al. 2005, Inaba, Branco et al. 2010).  
Crotalus venom contains SVMPs that cleave fibrinogen into fibrin split 
products (FSPs) in such a manner that renders it useless for fibrin clot formation 
(Martinez, Holburn et al. 1974, Pandya, Rubin et al. 1983). Studies have 
demonstrated that FSPs are capable of increasing fibrinogen plasma levels by 
inducing endogenous production of fibrinogen in hepatocytes (Fuller, Otto et al. 
1985, Princen, Moshage et al. 1985, Amrani 1990). This distinctive degradation 
of fibrinogen by Crotalus SVMPs presents an opportunity to harness the toxic 
potential of the venom to elicit an endogenous response to increase plasma 
fibrinogen levels. 
 
Research Questions, Hypotheses, and Specific Aims 
Over 200 million major elective surgeries are performed worldwide per 
year (Weiser, Regenbogen et al. 2008). With the rising costs of healthcare, 
preventive measures grow increasingly relevant to medical practice. Having 
established that SBI is an ideal platform for preconditioning and Crotalus venom 
as a promising therapeutic agent, we propose that preconditioning with small 
doses of Crotalus snake venom, known for both their inflammatory and 
hemorrhagic effects, will lead to increase tolerance to SBI. As discussed, the 
inflammatory and hemorrhagic nature of Crotalus venoms makes them a prime 
candidate to expand PC therapy for preventing SBI-induced brain edema and 
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hemorrhage. In our studies, we hope to open a new avenue of therapy for SBI 
using Crotalus venoms by utilizing their toxic properties to preemptively 
upregulate the endogenous response to inflammatory and hemorrhagic injury 
prior to SBI onset. 
Our central hypothesis is that preconditioning with Crotalus venom (Cv-PC), 
which consists of PLA2 and SVMPs, will temper the severity of SBI by inducing 
innate tolerance to injury. We propose to systematically examine the effects of 
high and low doses and investigate the molecular mechanisms of Cv-PC by the 
following study aims: 
Aim 1: The mechanism of edema prevention by Cv-PC is via the PLA2/COX-2 
inflammatory signaling pathway.  
Our corollary hypothesis is that Cv-PC will downregulate the response of 
the PLA2/COX-2 to injury, thereby reducing the inflammatory response. We will 
evaluate brain water content after Cv-PC, the expression of COX-2 after SBI, and 
evaluate the effects of antagonizing COX-2 while administering Cv-PC. 
Aim 2: The mechanism of reduced hemorrhage by Cv-PC is via fibrinogen 
cleavage.  
Our corollary hypothesis is that fibrinogen is cleaved by SVMP, increasing 
fibrinogen split products, leading to increased biosynthesis of plasma fibrinogen, 
ultimately improving clotting and reducing hemorrhage volume. We will measure 
hemorrhage volume, plasma fibrinogen and fibrinogen split product 
concentrations, determine coagulative parameters, and evaluate the effects of 
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antagonizing SVMP in Cv-PC. We will also fractionate the venom in order to 
identify the active venom components in Cv-PC. 
Our long-term goal is to develop an effective, preemptive therapy for SBI 
that will improve patient outcome and decrease costs of perioperative care for 
neurosurgical patients. We hope to establish a better mechanistic understanding 
of SBI that will facilitate the application of preconditioning therapies in clinical 
practice.  
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Figure 2.1. Schematic of Specific Aims.  AA: arachidonic acid; COX-2: 
cyclooxygenase-2; IL-6: interleukin-6; MMP: matrix metalloproteinase; PG: 
prostaglandins; PGH2: prostaglandin H2; PLA2: phospholipase 2; SVMP: snake 
venom metalloproteinase. 
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CHAPTER THREE 
CROTALUS SNAKE VENOM PRECONDITIONING REDUCES 
POSTOPERATIVE BRAIN EDEMA AND IMPROVES NEUROLOGICAL 
OUTCOMES AFTER SURGICAL BRAIN INJURY 
Introduction 
The delicate and complex architecture of the brain presents significant 
challenges for neurosurgery. To date, developing less invasive surgical methods 
(Decq, Le Guerinel et al. 1998, Gerzeny and Cohen 1998) and administering 
nonspecific postoperative care (Bruder and Ravussin 1999, Hellwig, Bertalanffy 
et al. 2003) have been the predominant strategies for limiting surgical brain injury 
(SBI). However, relatively little research exists that focuses on understanding 
SBI’s pathophysiology or developing therapies to target specific pathways. 
Previous studies have established that brain edema develops several hours after 
SBI and is likely the result of compromised BBB integrity (Matchett, Hahn et al. 
2006, Jadhav, Matchett et al. 2007). SBI-induced brain edema requires vigilant 
postoperative care and may lengthen hospital stay. Thus, reducing brain edema 
caused by SBI would have a significant impact on both patient outcome and 
perioperative costs. 
The elective nature of many neurosurgical procedures makes SBI a prime 
candidate for preventative therapy. Preconditioning (PC) utilizes normally harmful 
methods which, when given well-below toxic levels, induce minimal damage to 
elicit the body’s innate response and reduce damage from the full-insult. While 
PC studies have shown promising neuroprotective effects for other models of 
	  40 
brain injury (Wada, Ito et al. 1996, Kapinya, Lowl et al. 2002), clinical translation 
is limited in these models since these injuries develop spontaneously. Currently, 
hyperbaric oxygen preconditioning (HBO-PC) is the only preconditioning modality 
that has been studied in animal model of SBI. HBO-PC was shown to decrease 
brain water content and improve neurological function 24 h following SBI; these 
effects were eradicated with cyclooxygenase-2 (COX-2) inhibition (Jadhav, 
Ostrowski et al. 2009). Furthermore, SBI-induced COX-2 overexpression was 
tempered by HBO-PC, highlighting the PLA2/COX-2 pathway as promising target 
for therapy. 
 Snake venom toxins have long been studied for potential therapeutic 
applications. Crotalus helleri venom contains phospholipase 2 (PLA2), an 
enzyme upstream to COX-2 in the inflammatory cascade, that converts 
membrane phospholipids into arachidonic acid, which eventually leads to the 
production of prostaglandins and thromboxanes (Bush and Siedenburg 2000; 
French et al. 2004).	  We hypothesize that Cv-PC will downregulate the response 
of the PLA2/COX-2 pathway to injury, thereby reducing the inflammatory 
response after SBI. 
 
Results 
Cv-PC Reduces Brain Water Content after SBI 
 At 24 h after SBI, the vehicle-treated animals were observed to have 
increased brain water content of 83.1 ± 0.2%, which was significantly higher than 
that of sham animals, whose brain water content was 80.2 ± 0.1%. Similarly, the 
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brain water content of vehicle-treated animals at 72 h post-SBI was elevated at 
83.3 ± 0.2%. Cv-PC-treated animals with doses of 20% LD50 had significantly 
reduced brain water content at both 24 h and 72 h after SBI compared to vehicle-
treated animals, while Cv-PC with 10% LD50 doses showed brain water content 
that was lower but not statistically significant (Figure 3.1B). 
 
Cv-PC Improves Neurological Function after SBI 
To assess the neurological function after Cv-PC, the modified Garcia 
neurological scores were assessed (Figure 1C). All animals that received SBI 
scored significantly lower than sham-animals (20.5 ± 0.2). At 24 h and 72 h post-
SBI, Cv-PC-treated animals (18.3 ± 0.3 and 18.2 ± 0.4, respectively) scored 
significantly higher than vehicle-treated animals (16.4 ± 0.4 and 15.8 ± 0.6, 
respectively). 
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Figure 3.1. Cv-PC reduces brain edema and improves neurological function in 
SBI. (A) Schematic timeline of treatments and outcomes; rats received three 
subcutaneous injections of vehicle (normal saline) or Cv-PC doses (10% or 20% 
of the LD50 dose) at 72 h, 48 h, 24 h prior to surgery. (B) Cv-PC (20% LD50 
dose) significantly reduced brain water content at 24 h and 72 h after SBI 
compared to those of vehicle-treated animals. (C) Cv-PC (20% LD50 dose) 
improved modified Garcia scores at 24 h and 72 h after SBI compared to those of 
vehicle-treated animals.  * p<0.05 vs sham # p<0.05 vs vehicle (24 h), ✝ p<0.05 
vs vehicle (72 h). Data are shown as mean ± SEM, n=5-7 all groups. 1-way 
ANOVA, with Tukey’s comparisons, was used to determine differences. 
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COX-2 Inhibition Reverses Cv-PC Effects on Brain Water Content and 
Neurological Function after SBI 
 To evaluate the role of COX-2 in Cv-PC against SBI, NS398, a COX-2 
inhibitor, was administered one hour prior to each Cv-PC dose. This abolished 
the decrease in brain water content by Cv-PC (Figure 3.2B) to levels comparable 
to vehicle-treated animals. Additionally, COX-2 inhibition by NS398 reversed the 
protective effects of Cv-PC on neurological function at 24 h post-SBI (Figure 
3.2C) 
 
Cv-PC Reduces Expression of Inflammatory Mediators COX-2 and PGE2 in 
SBI 
 At 24 h following SBI, levels of COX-2 were increased in vehicle-treated 
animals, as expected. The expression of COX-2 was significantly reduced in Cv-
PC-treated animals. COX-2 inhibition during Cv-PC treatment abolished this 
protective effect but provoked COX-2 expression at 24 h post-SBI (Figure 3.3). 
To assess the effects of Cv-PC on downstream inflammatory mediators, PGE2 
was evaluated by immunohistochemistry. Cv-PC appeared to diminish the 
expression of PGE2 at 24 h following SBI compared to that of vehicle-treated 
animals (Figure 3.4). 
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Figure 3.2. COX-2 Inhibition Reverses Cv-PC Effects. (A) Schematic timeline of 
treatments and outcomes; rats received three subcutaneous injections of vehicle 
(normal saline) or Cv-PC doses (20% LD50 dose) at 72 h, 48 h, 24 h prior to 
surgery. (B) Treatment with NS398 (COX-2 inhibitor, 10 mg/kg) prior to Cv-PC 
administration abolished the protective effects on brain water content. (C) 
Treatment with NS398 prior to Cv-PC administration reversed Cv-PC 
improvement of modified Garcia neurological scores. * p<0.05 vs sham, # p<0.05 
vs vehicle. Data are shown as mean ± SEM, n=5-7 all groups. 1-way ANOVA, 
with Tukey’s comparisons, was used to determine differences. 
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Figure 3.3. COX-2 Western Blot Analysis. COX-2 expression was significantly 
decreased after Cv-PC. Co-administration of Cv-PC and NS398, a COX-2 
inhibitor reversed this effect. * p<0.05 vs Sham, # p<0.05 vs Vehicle. Data are 
shown as mean ± SEM, n=5/group. 1-way ANOVA, with Tukey’s comparisons, 
was used to determine differences. 
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Figure 3.4. Immunohistological staining of ipsilateral frontal lobe tissue near the 
resection site using inflammatory marker PGE2 (green). (A) Sham. (B) Vehicle. 
(C) Cv-PC. Cv-PC attenuated PGE2 expression compared to that of the vehicle 
group. n=2/group. 
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Discussion 
Brain edema is a serious complication of neurosurgery. Given the fixed 
space within the cranium, postoperative brain edema can lead to devastating 
complications such as brain herniation (Bruder and Ravussin 1999). This study 
presents a novel preconditioning method to reduce brain edema by prompting 
endogenous protective mechanisms prior to injury. Our hypothesis was that Cv-
PC would attenuate the increase in brain water content by SBI. We observed that 
Cv-PC reduces brain water content by approximately 1.2% and improves 
neurological function after SBI. Our results suggest that this neuroprotection is 
conferred through the PLA2/COX-2 pathway, as inhibition of COX-2 reversed the 
protective effects of Cv-PC. 
Our results correspond to other SBI rodent studies that indicate that the 
brain water content of tissue surrounding the resection site is increased by 3-4% 
during the first three days post-surgery (Matchett et al. 2006; Yamaguchi et al. 
2007). At first glance, this 4% increase in brain water content may seem trivial, 
yet this extra 4% water content translates into a 25% increase in tissue volume, 
leading to high intracranial pressure, hypoperfusion of neurons, and cell death 
(Marmarou et al. 2000; Keep et al. 2012). Additionally, our results are congruent 
with previous studies with HBO-PC, which has been shown to attenuate COX-2 
expression and brain water content, and improve functional outcome (Jadhav et 
al. 2009). Despite its promising results, HBO-PC continues to be limited by the 
lack of congruity in dosing regimens and the potential for oxygen toxicity. Like 
HBO-PC, Cv-PC appears to mitigate SBI brain edema and neurological injury by 
	  48 
tempering the expression of COX-2. Further purification and characterization of 
C. helleri proteins are needed to explore the clinical feasibility of Cv-PC. 
 
Materials and Methods 
Animal Experiments 
All animals were housed in cages on a constant 12-hour light/dark cycle 
with controlled temperature and were given food and water ad libitum. 65 male 
Sprague Dawley rats (280-330g) were divided to the following treatment 
groups—sham, vehicle, Cv-PC, Cv-PC+NS3983 (COX-2 inhibitor, Abcam, 
ab120295). Vehicle and Cv-PC animals received either three daily subcutaneous 
doses of saline or C. helleri venom (20% of the LD50; 0.36 mg/kg) at 72 h, 48 h, 
and 24 h prior to blood draw or surgery. Sham animals received craniotomy only. 
SBI animals underwent craniotomy and a partial right frontal lobe resection 1mm 
above the horizontal line from bregma and 2mm to the right of the vertical line 
from bregma down to the skull base as previously described (Matchett, Hahn et 
al. 2006, Jadhav, Solaroglu et al. 2007). In Cv-PC+NS398 animals, NS398 (10 
mg/kg, Abcam) was administered intraperitoneally one hour prior to Cv-PC 
doses, as previously described (Jadhav, Ostrowski et al. 2009) 
 
Neurological Testing 
A blinded observer tested all surviving animals 24 h after brain injury, 
using a modified 21-point sensorimotor test that measures spontaneous activity, 
body proprioception, response to vibrissae touch, limb symmetry, lateral turning 
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ability, forepaw outstretching, and climbing ability, with a maximum of 3 points 
designated for each category (Garcia, Wagner et al. 1995) 
 
Brain Water Content 
After neurological testing, animals were sacrificed at 24 h for brain 
harvesting. Brains were divided into ipsilateral and contralateral frontal and 
parietal lobes, cerebellum, and brainstem. These sections were weighed 
immediately (wet weight), then placed in a 100 degree Celsius oven for 48 h 
before being weighed again (dry weight). Brain water content was calculated as a 
percentage via the following formula: [(wet weight – dry weight)/(wet weight)] x 
100% (Tang, Liu et al. 2004). 
 
Western Blot 
At 24 h after SBI, animals were euthanized with isoflurane and perfused 
transcardially with cold PBS. Brains were divided into hemispheres and stored at 
-80°C until analysis. Whole-cell lysates were obtained by gently homogenizing in 
RIPA lysis buffer (Santa Cruz Biotechnology, Inc., sc-24948) and centrifuging 
(14,000 g at 4°C for 30 min). The supernatant was collected and the protein 
concentration was determined using a detergent compatible assay (Bio-Rad, Dc 
protein assay). Equal amounts of protein (30 µg) were loaded and subjected to 
electrophoresis on an SDS-PAGE gel. After being electrophoresed and 
transferred to a nitrocellulose membrane, the membrane was blocked and 
incubated with the primary antibody overnight at 4°C. For the primary antibody 
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goat polyclonal to COX-2 1/500 (Santa Cruz, SC-1745) was used. The same 
membrane was probed with an antibody against β-actin (Santa Cruz, 1:1000) for 
an internal control. Incubation with secondary antibodies (Santa Cruz 
Biotechnology) was done for 1 h at room temperature. Immunoblots were then 
probed with an ECL Plus chemiluminescence reagent kit (Amersham 
Biosciences, Arlington Heights, IL) and visualized with an imaging system (Bio-
Rad, Versa Doc, model 4000). Data was analyzed using Image J software.  
 
Immunohistochemistry 
The coronal sections (10 µm thickness) containing the bilateral frontal 
lobes were cut on a cryostat (Leica Microsystems, Bannockburn, IL) and 
mounted on poly-L-lysine–coated slides. Sections were incubated overnight at 
4°C with goat polyclonal antibody to COX-2 (Santa Cruz, SC-1745). Appropriate 
fluorescence dye–conjugated secondary antibodies (Jackson Immunoresearch, 
West Grove, PA) were applied in the dark for 1 hour at room temperature. For 
negative controls, the primary antibodies were omitted and the same staining 
procedures were performed. The sections were visualized with a fluorescence 
microscope, and the photomicrographs were saved and merged with Image Pro 
Plus software (Olympus, Melville, NY). 
 
Statistical Analysis 
All values are mean ± SEM. GraphPad Prism software was used for 
statistical analysis. As specified in each figure legend, 1-way ANOVA, with 
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Tukey’s comparisons, was used to determine differences among 3 or more. A P 
value <0.05 was considered significant. 
 
Study Approval 
All animal husbandry and procedures were approved by the Institutional 
Animal Care and Use Committee. 
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CHAPTER FOUR 
CROTALUS ATROX VENOM PRECONDITIONING INCREASES PLASMA 
FIBRINOGEN AND REDUCES PERIOPERTIVE HEMORRHAGE IN SURGICAL 
BRAIN INJURY RATS 
Introduction 
Perioperative bleeding is a serious complication in patients undergoing 
neurosurgical procedures (Bruder and Ravussin 1999, Seifman, Lewis et al. 
2011). Intraoperative hemorrhage lengthens and complicates surgery and may 
trigger further injury by tissue hypo-perfusion or disruption of the blood-brain 
barrier (Bruder and Ravussin 1999, Sulejczak, Grieb et al. 2008). Postoperative 
hemorrhage poses a significant threat, given the finite nature of the intracranial 
space. Even small hematomas may result in increased intracranial pressure and 
brain herniation. Thus, the optimization of perioperative hemostasis in 
neurosurgical patients is of paramount importance.  
The surgical brain injury (SBI) rodent model has been established to 
mimic injury during brain resection (Matchett, Hahn et al. 2006, Jadhav, 
Solaroglu et al. 2007). Given the elective nature of most neurosurgical 
procedures, the surgical brain injury (SBI) model is an ideal platform for 
preconditioning (PC) modalities, which are preemptive therapies in which mildly 
harmful stimuli are administered to induce endogenous protective mechanisms 
prior to major injury. PC has shown to be protective in the SBI model (Jadhav, 
Ostrowski et al. 2009, Jadhav, Ostrowski et al. 2010), as well as in many other 
injury models (Wada, Ito et al. 1996, Kapinya, Lowl et al. 2002, Nie, Xiong et al. 
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2006, Sang, Cao et al. 2006, Peng, Ren et al. 2008, Costa, Constantino et al. 
2010).  
Fibrinogen, an acute phase reactant with a half-life of 3.74 days (Martinez, 
Holburn et al. 1974), is part of the coagulation cascade and provides the 
substrate for fibrin clot formation. During coagulation, thrombin cleaves 
fibrinogen, producing soluble fibrin monomers that are able to be cross-linked by 
factor VIIIa to form a network on which a clot is built; fibrinogen also plays a role 
in platelet aggregation (Franchini and Lippi 2012). Decreased plasma fibrinogen 
levels have been identified as a potential modifiable risk factor for perioperative 
bleeding in cardiothoracic and orthopedic surgeries (Ucar, Oc et al. 2007, 
Carling, Jeppsson et al. 2011, Galas, de Almeida et al. 2014, Pillai, Fraser et al. 
2014, Walden, Jeppsson et al. 2014). Lower perioperative fibrinogen levels, even 
within the normal reference range, have been shown to be associated with an 
increased risk of postoperative bleeding complications in patients undergoing 
elective intracranial surgery (Gerlach, Tolle et al. 2002, Adelmann, Klaus et al. 
2014).  
The hemostatic properties of snake venom toxins have long been studied 
for potential uses in clinical medicine.  Some are used to detect coagulative 
disorders in the medical laboratory, while others have been examined for treating 
patients with coagulopathies (Marsh 2001, Earl, Masci et al. 2012). Crotalus 
atrox rattlesnake venom contains snake venom metalloproteinases (SVMPs) that 
cleave fibrinogen into fibrin split products (FSPs) in such a way that renders the 
proteins useless in fibrin polymerization (Pandya, Rubin et al. 1983, Abou-Saleh, 
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Connell et al. 2009). FSPs have been previously shown to increase fibrinogen 
plasma levels by inducing endogenous production of fibrinogen in hepatocytes 
(Fuller, Otto et al. 1985, Princen, Moshage et al. 1985, Amrani 1990). The unique 
degradation of fibrinogen by C. atrox SVMPs—creating FSPs without the 
induction of clotting—presents an opportunity to harness the toxic nature of the 
venom to elicit an endogenous response to increase plasma fibrinogen levels 
prior to elective surgery. We hypothesize that C. atrox venom preconditioning 
(Cv-PC) prior to surgery will increase plasma fibrinogen, thereby decreasing 
perioperative bleeding in the rodent surgical brain injury model. 
 
Results 
Cv-PC Reduces Intraoperative Blood Loss In Vivo 
SBI resulted in an intraoperative hemorrhage volume of 1475 ± 75 µL 
which was significantly higher than that observed in sham animals (188 ± 23 µL). 
Twenty-four hours after Cv-PC, a dose-dependent reduction in intraoperative 
hemorrhage by 17.2% to 35.0% in Cv-PC-treated animals subjected to SBI—
1221± 70 µL, 991 ± 62 µL, and 958 ± 75 µL in the 10%, 20%, and 30% LD50 
doses, respectively (Figure 4.1B). Cv-PC with doses of 20% and 30% LD50 both 
significantly attenuated intraoperative hemorrhage compared to that of SBI 
animals given saline only (vehicle). 
 
Cv-PC Reduces Postoperative Hematoma In Vivo 
Next, the effect of Cv-PC on the development of postoperative hematoma 
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in the brain parenchyma was examined. Assessed at 24 h after SBI surgery, the 
postoperative hematoma demonstrated a dose-dependent decrease in volume 
by 48.7% to 64.9% for Cv-PC which was significantly decreased for all doses 
compared to that of SBI animals receiving vehicle preconditioning (Figures 4.1C). 
The postoperative hematoma volume in vehicle-treated animals was 22.5 ± 1.6 
µL, and that of Cv-PC-treated animals was 11.3 ± 1.2 µL, 8.0 ± 0.7 µL, and 7.9 ± 
0.5 µL in the 10%, 20%, and 30% LD50 doses, respectively.  
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Figure 4.1. Cv-PC reduces intraoperative hemorrhage and postoperative 
hematoma in a dose-dependent manner in SBI. (A) Schematic timeline of 
treatments and outcomes; treatment group rats received three subcutaneous 
doses of vehicle (normal saline) or Cv-PC (10%, 20%, and 30% of the LD50 
dose) at 72 h, 48 h, 24 h prior to surgery; sham animals received craniotomy 
only; intraoperative hemorrhage volume was collected throughout surgery and 
postoperative hematoma was collected at 24 h post-surgery. (B) Intraoperative 
hemorrhage and (C) postoperative hematoma volumes were assessed by 
spectrophotometric hemoglobin assay; both were reduced by subcutaneous Cv-
PC in a dose-dependent manner. Cv-PC: Crotalus atrox venom preconditioning; 
SBI: surgical brain injury. * p<0.05 vs Sham, # p<0.05 vs Vehicle. Data are 
shown as mean ± SEM, n=5-6 all groups. 1-way ANOVA, with Tukey’s 
comparisons, was used to determine differences. 
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Cv-PC Increases Plasma Fibrinogen and Plasma FSPs In Vivo 
To assess the hematologic effects of Cv-PC, coagulation parameters were 
measured following administration of vehicle or Cv-PC at 24 h following the third 
dose of Cv (corresponding to the intended surgery time) or at 6 h post-surgery in 
animals that received SBI (Figure 4.2A). Animals that received Cv-PC showed 
significantly increased plasma fibrinogen at time of surgery, as well as at 6 h 
postoperatively (Figure 4.2B, Table 4.1). By time of surgery, Cv-PC raised 
plasma fibrinogen by an average of 78.4 mg/dL—a 31.6% increase in 
concentration. At 6 h post-SBI, the fibrinogen remained higher in the Cv-PC-
treated animals than that of Vehicle treated animals. FSPs were only detected in 
the plasma of Cv-PC-treated animals.  
 
PT, INR, PTT, D-Dimer, and Soluble Fibrin Remain Normal After Cv-PC 
To assess Cv-PC’s potential for inducing coagulopathic events we 
measured PT, INR, PTT, D-Dimer, and soluble fibrin. We did not observe 
clinically significant changes in these parameters following Cv-PC (Table 4.1). 
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Figure 4.2. Cv-PC increases plasma fibrinogen and generates fibrin split 
products. (A) Schematic timeline of treatments and outcomes; rats received three 
subcutaneous injections of vehicle (normal saline), Cv-PC doses (20% of the 
LD50 dose), or Cv-PC doses incubated with matrix metalloproteinase inhibitor 
(MMP-I; with equal concentrations of Marimastat and AG-3340 to Cv) at 72 h, 48 
h, 24 h prior to blood draw by cardiac puncture or surgery; animals undergoing 
surgery received blood draws at 6 h post-surgery. (B) Cv-PC significantly 
increased plasma fibrinogen at the time of surgery and at 6 h post-surgery. (C) 
Fibrin split products are only detectable in the plasma of Cv-PC-treated animals. 
MMP inhibition suppressed formation of FSPs by Cv-PC. # p<0.05 vs Vehicle, ✝ 
p<0.05 vs Vehicle+SBI, ‡ p<0.05 vs Cv-PC. Data are shown as mean ± SEM, 
n=8-12 all groups. 1-way ANOVA, with Tukey’s comparisons, was used to 
determine differences. 
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Table 4.1.	  Coagulation parameters after Cv-PC. 
 
Data are shown as mean ± SEM. Cv-PC, C. atrox venom preconditioning; FSPs, 
fibrin split products; INR, international normalized ratio; MMP-I, metalloproteinase 
inhibitor; PTT, partial thromboplastin time; PT, prothrombin time; SBI, surgical 
brain injury. * p<0.05 vs Vehicle. 
   
 Vehicle Cv-PC Cv-PC +MMP-I Vehicle+SBI Cv-PC+SBI 
n = 12 10 10 10 8 
Fibrinogen  
(mg/mL) 
248.9 ± 
4.9 
327.6 ± 
9.1* 271.0 ± 10.6 273.2 ± 7.6 356.9 ± 17.6* 
FSPs  
(µg/mL) 0.0 ± 0.0 26.0 ± 9.6 1.0 ± 1.0 0.0 ± 0.0 10.0 ± 0.0 
PT  
(sec) 
10.67 ± 
0.05 
10.52 ± 
0.05 10.34 ± 0.08 10.25 ± 0.10 10.04 ± 0.07 
INR 0.97 ± 0.01 
0.92 ± 
0.01 0.93 ± 0.01 0.91 ± 0.01 0.90 ± 0.00 
PTT  
(sec) 
15.07 ± 
0.15 
14.76 ± 
0.04 15.32 ± 0.38 15.16 ± 0.12 14.83 ± 0.04 
D-Dimer  
(µg/mL) 
0.03 ± 
0.01 0.0 ± 0.0 0.04 ± 0.02 0.01 ± 0.01 0.06 ± 0.01 
Soluble 
Fibrin 
(ng/mL) 
41.8 ± 8.9 65.6 ± 8.1 48.2 ± 10.2 39.5 ± 6.7 80.8 ± 11.3* 
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PC with Several Cv Fractions Reduces Intraoperative Hemorrhage and 
Postoperative Hematoma Volumes In Vivo 
Whole Cv and its fractions from gel filtration separation were separated by 
reversed-phase HPLC (Figures 4.3A and 4.3B), and fraction components of all 
substantial peaks were identified by LC-MS. Gel filtration Cv fractions 1, 2, 3, 4, 5 
and pooled fractions 6-8 were then used for Cv-PC. Cv-PC with fractions 2, 3, 4, 
and 5 improved hemorrhage volumes. 
 
MMP Inhibition Blocks Cv-PC Effects on Hemorrhage Volumes, Plasma 
Fibrinogen and FSPs 
To evaluate the role of SVMPs in Cv-PC against SBI, two MMP inhibitors 
were coadministered with Cv for each injection during Cv-PC. The concomitant 
administration of MMP inhibitors abolished the increase in plasma fibrinogen by 
Cv-PC (Figure 4.2B, Table 4.1) to levels similar to that of vehicle PC animals. 
Additionally, Cv-PC administered with MMP inhibitors significantly diminished the 
generation of FSPs (Figure 4.2C, Table 4.1). Furthermore, SVMP inhibition by 
MMP inhibitors had similar intraoperative hemorrhage and postoperative 
hematoma volumes to those of vehicle treated animals, which were significantly 
higher than those of Cv-PC animals (Figure 4.4B, 4.4C). 
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Figure 4.3. Reversed-Phase HPLC and Gel Filtration Chromatographs of C. atrox 
Venom. (A) Reversed-Phase HPLC of crude C. atrox venom (Cv) and Cv 
fractions (Fr) collected from gel filtration chromatography; absorbance at 214 nm. 
Grey demarcates the range in which snake venom metalloproteinases (SVMPs) 
represent the prominent Cv component as identified by LC-MS   (B) Gel Filtration 
Chromatograph of Cv fractionation. Collected fractions are labeled in red 
numbers. 
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Figure 4.4. Cv-PC intraoperative hemorrhage and postoperative hematoma in 
SBI. (A) Schematic timeline of treatments and outcomes; rats received three 
subcutaneous doses of vehicle (normal saline), Cv-PC (20% of the LD50 dose), 
Cv-PC doses incubated with matrix metalloproteinase inhibitor (MMP-I; with 
equal concentrations of Marimastat and AG-3340 to Cv), or fractions (Fr) of Cv at 
72 h, 48 h, 24 h prior to surgery. Sham animals received craniotomy only. 
Fibrinogen-treated animals received one dose of fibrinogen (Fb,15mg/1.5mL) 15 
min before surgery. Routes of dose administration were either subcutaneous (sc) 
or intravenous (iv). Intraoperative hemorrhage volume was collected throughout 
surgery and postoperative hematoma was collected at 24 h post-surgery. (B) 
Intraoperative hemorrhage volume was significantly reduced by Cv-PC (20% 
LD50) and Cv-PC by Fr 2, 3, and 4. MMP inhibition during Cv-PC reversed the 
effect. Direct administration of fibrinogen reduced intraoperative hemorrhage.  
(C) Postoperative hematoma volume was significantly decreased by Cv-PC (20% 
LD50) and Cv-PC by all fractions. MMP inhibition during Cv-PC reversed the 
effect. Direct administration of fibrinogen reduced the development of 
postoperative hematoma. * p<0.05 vs Sham, # p<0.05 vs Vehicle, ‡ p<0.05 vs 
Cv-PC (20% LD50). Data are shown as mean ± SEM, n=5-6 all groups. 1-way 
ANOVA, with Tukey’s comparisons, was used to determine differences. 
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Direct Fibrinogen Administration Reduces Intraoperative Hemorrhage and 
Postoperative Hematoma Volumes In Vivo 
To determine the effect of direct fibrinogen administration on SBI 
pathophysiology, 15 mg/1.5 mLof fibrinogen was administered 15 min prior to 
induction of surgery. In fibrinogen-treated animals, a reduction of intraoperative 
hemorrhage (Figure 4.4B) and postoperative hematoma volumes (Figure 4.4C) 
were observed comparable to those of Cv-PC-treated animals.  
 
C. atrox Venom Causes Dose-dependent Hemostatic Changes in Human 
Whole Blood In Vitro 
To begin assessing the clinical feasibility of Cv-PC, the direct effects of Cv 
on whole human blood was evaluated for clotting, sticking, and clumping 
parameters. No change in any of these measures was found for saline; however, 
a dose-dependent increase in all three parameters was observed at 2 µg/mL, 4 
µg/mL, and 8 µg/mL doses of Cv.  
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Figure 4.5. Dose-dependent effects of C. atrox venom on human whole blood in 
vitro. Minimal stimulation clotting/platelet testing imitates in vivo clotting on a 
sample of whole blood and measures three parameters—clot, clump, stick times. 
Clot time correlates with fibrinogen, intrinsic / extrinsic pathway function, whereas 
clump and stick times correlate well with platelet function. We observed a dose-
dependent increase in (A) Clotting time (B) Stick time (C) Clump time at (2, 4, 
and 8 µg/mL of C. atrox venom. Data are shown as mean ± SEM, n=3 all groups. 
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Discussion 
 
Perioperative hemorrhage is a devastating complication in neurosurgery 
(Bruder and Ravussin 1999, Seifman, Lewis et al. 2011), making optimization of 
hemostasis of the utmost importance. This study uses a novel preemptive 
approach for improving perioperative hemostasis by eliciting endogenous 
mechanisms using C. atrox venom preconditioning. Our hypothesis was that Cv-
PC would attenuate the hemorrhage induced by SBI via an increase of 
endogenous fibrinogen production. First, we observed that Cv-PC reduces 
intraoperative blood loss and postoperative hematoma by more than 30% in the 
SBI rodent model. Second, while coagulation was improved by Cv-PC, 
coagulation parameters—PT, INR, PTT, D-Dimer, and soluble fibrin—showed no 
indication that Cv-PC caused a thrombotic state. Third, our results point to SVMP 
as the active component of Cv that cleaves fibrinogen into FSPs and imparts the 
protective effects of Cv-PC; and inhibition of SVMP reversed the effects of Cv-
PC. Finally, preconditioning with Cv fractions which primarily contain SVMP 
retained the effects of Cv-PC by crude venom.  
 
Choice of Crotalus Venom 
Given the ability of Crotalus venoms to generate FSPs without the 
initiation of clotting (Pandya, Rubin et al. 1983, Abou-Saleh, Connell et al. 2009) 
and the previously demonstrated induction by FSPs of hepatocyte fibrinogen 
production (Fuller, Otto et al. 1985, Princen, Moshage et al. 1985, Amrani 1990), 
C. adamanteus, C. atrox, and C. viridis helleri venoms were considered for PC. 
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We elected to use C. atrox venom because it has been demonstrated to have 
strong fibrinolytic activity with no detectable fibrinogen clotting activity, whereas 
the other Crotalus venoms were measured to have a some fibrinogen clotting 
activity (Bajwa, Markland et al. 1981). To determine the optimal dose of venom 
that can elicit therapeutic benefit to animals subjected to SBI, a dose dependent 
study was conducted in which we administered three daily doses of Cv (10%, 
20%, and 30% of the LD50; 1.85 mg/kg, 3.7 mg/kg, and 5.55 mg/kg, 
respectively) with the last dose 24 h prior to surgery. The results of the dose 
dependent study suggest that the effectiveness of Cv-PC for reducing 
intraoperative hemorrhage and postoperative hematoma volumes plateaus at the 
20% LD50 dose. Additionally, these data suggest that Cv-PC is viable treatment 
to improve hemostasis in the SBI neurosurgical model. 
 
Effects of Cv on Coagulation 
Prothrombrin time (PT), international normalized ratio (INR), and partial 
thromboplastin time (PTT) are routinely assessed to evaluate the extrinsic and 
intrinsic pathways of the coagulation cascade. Increased INR or prolongation of 
PT or PTT is suggestive of bleeding diathesis. Shortened PTT may be 
associated with increased risk of venous thromboembolism (Tripodi, 
Chantarangkul et al. 2004). D-Dimer and soluble fibrin levels are used to screen 
for disseminated intravascular coagulation (DIC), which is characterized by 
systemic activation of blood coagulation and subsequent formation of 
microvascular thrombi that may ultimately lead to severe bleeding by 
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consumptive depletion of coagulation factors and/or platelets (Levi and Ten Cate 
1999). The findings that Cv-PC had no clinically significant effect on any of these 
parameters supports previous findings that C. atrox venom has limited clotting 
activity (Bajwa, Markland et al. 1981). 
 
 
Identifying the Role of SVMP in PC Against SBI 
Initially, Cv was fractionated by reverse-phase chromatography, which 
may denature proteins, and is therefore unsuitable for assays of biological 
activity; thus, gel filtration chromatography, which preserves protein activity but 
achieves much lower resolution in protein separation than reversed-phase 
chromatography was utilized to obtain 9 fractions. These fractions were 
administered intravenously to assure intravascular exposure to the Cv 
components. In both intraoperative and postoperative hemorrhage volumes, 
fractions 2, 3, and 4, which contain primarily SVMPs (Figure 3), provided 
improved hemostasis most consistently. 
To further elucidate SVMP as the active protein responsible for increased 
homeostasis during SBI, we evaluated the effects of blocking SVMP during Cv-
PC. Since specific inhibitors of SVMP are not available, we elected to use 
commercially available MMP inhibitors, Marimastat and AG-3340, which have 
been previously described to block other SVMPs (Howes, Theakston et al. 2007). 
Our findings, that coadimistration of MMP inhibitors and Cv during PC prevents 
Cv-PC benefits, suggest that SVMP plays a crucial role in the generation of FSPs 
and fibrinogen, as well as in the improved hemostasis conferred by Cv-PC. 
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Investigation of the Role of Fibrinogen in Cv-PC 
To determine of fibrinogen was the key mediator of Cv-PC effect after SBI, 
fibrinogen treatment was given 15 minutes before SBI (15 mg/1.5 mLof 
fibrinogen). This dose was determined by computing the required amount of 
protein to raise plasma fibrinogen by approximately 75 mg/dL, given the 
estimated blood volume of the animals, as previously published (Diehl, Hull et al. 
2001). Our results showed that this dose of fibrinogen, which correlates with the 
increase in fibrinogen concentration provided by Cv-PC, was capable of 
improving perioperative hemostasis. 
 
Clotting, Clumping, and Sticking Tests 
Minimal stimulation clotting/platelet testing, which imitates in vivo clotting 
on a sample of whole blood, measures three parameters—clot, clump, and stick 
times. Clot time correlates with fibrinogen, intrinsic / extrinsic pathway function, 
whereas clump and stick times correlate well with platelet function.  A dose 
dependent reduction in all three parameters demonstrates impaired clotting 
function by Cv. The prolonged clot time likely represents the depletion of 
fibrinogen by SVMP cleavage. The prolonged clump and stick times indicate 
decreased platelet function, which likely results from fibrinogen depletion, as 
platelets are supported by fibrinogen to mediate adhesion and aggregation 
(Coller, Peerschke et al. 1983, Ikeda, Handa et al. 1991, Savage and Ruggeri 
1991). 
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Clinical Application of Increasing Plasma Fibrinogen Levels Before Major 
Elective Surgery 
Our findings are congruent with the growing body of literature that 
emphasizes plasma fibrinogen level as a potential modifiable risk factor for 
perioperative hemorrhage (Gerlach, Tolle et al. 2002, Ucar, Oc et al. 2007, 
Carling, Jeppsson et al. 2011, Adelmann, Klaus et al. 2014, Galas, de Almeida et 
al. 2014, Pillai, Fraser et al. 2014, Walden, Jeppsson et al. 2014). These studies 
indicate that lower fibrinogen, even within normal limits, are correlated with 
increased bleeding and that higher levels of fibrinogen are associated with better 
outcomes. Fibrinogen is fundamental to effective clot formation. It circulates at 
the highest concentration of all the coagulation factors (Lowe, Rumley et al. 
2004) and is the first coagulation factor to drop to critically low levels during 
major hemorrhage. Dilutional deficiency of fibrinogen develops earlier than any 
other hemostatic abnormality when plasma-poor red blood cell preparations are 
used to replace blood loss (Hiippala, Myllyla et al. 1995). Yet in current practice, 
the options for increasing plasma fibrinogen are limited to transfusions of 
fibrinogen-containing preparations like fresh frozen plasma, cryoprecipitate, and 
fibrinogen concentrate. Fresh frozen plasma (FFP) varies in fibrinogen 
concentration as it is collected from donors. The concentration of fibrinogen in 
FFP reportedly ranges between 100-300 mg/dL (Theusinger, Baulig et al. 2011). 
Because of these concentrations, large volumes of FFP are necessary for even 
modest increases in plasma fibrinogen. Cryoprecipitate, obtained by 
concentrating FFP, has about 200 mg of fibrinogen per unit at a concentration of 
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about 550 mg/dL (Lee, Lee et al. 2014). Fibrinogen concentrate, manufactured 
from human plasma and available as a pasteurized, lyophilized powder, is given 
at a concentration of 2000 mg/dL (Levy, Szlam et al. 2012). A previous study 
determined that in order to raise plasma fibrinogen levels from 150 mg/dL to 170 
mg/dL, 14 units of FFP, 8 units of cryoprecipitate, or 2 units of fibrinogen 
concentrate is required (Collins, Solomon et al. 2014); thus, fibrinogen 
supplementation by FPP and cryoprecipitate administration may cause fluid 
overload. In addition, these transfusions are not without risk; they are associated 
with complications that include allergic reaction, infections, and transfusion-
related acute lung injury (Busch, Glynn et al. 2005, Inaba, Branco et al. 2010).  
 An estimated 31% of elective neurosurgeries require blood transfusions 
(Bhatnagar 2007). A preventive therapy that reduces perioperative hemorrhage 
would decrease the need for blood transfusions, ultimately cutting perioperative 
costs; up to $6.03 million is spent on blood and transfusion-related care for 
surgical patients annually per hospital (Shander, Hofmann et al. 2010). While our 
study focused on Cv-PC in the SBI model, the implications of our results extend 
beyond the field of neurosurgery. Cv-PC could also be applied to elective 
surgeries in other fields, as perioperative hemorrhage is the bane of surgeons in 
every specialty. Over 200 million major elective surgeries are performed 
worldwide per year (Weiser, Regenbogen et al. 2008). Additional studies are 
needed to assess the translational feasibility of Cv-PC. Further isolation and 
characterization of proteins responsible are required to establish mechanism and 
safety. While our study demonstrated that Cv-PC did not result in coagulation 
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parameters indicative of a thrombotic state, more studies are needed to assess 
whether the Cv-PC increases the risk of pathologic thrombotic events.  
 
Materials and Methods 
Animal Experiments 
All animals were housed in cages on a constant 12-hour light/dark cycle 
with controlled temperature and were given food and water ad libitum. 121 male 
Sprague Dawley rats (280-330g) were divided to the following treatment 
groups—sham, vehicle, Cv-PC (various doses and fractions), Cv-PC+MMP-I, 
fibrinogen. Vehicle and Cv-PC animals received either three daily subcutaneous 
doses of saline or C. atrox venom (10%, 20%, and 30% of the LD50; 1.85 mg/kg, 
3.7 mg/kg, and 5.55 mg/kg, respectively, for the dose dependent study and 20% 
LD50 for the remainder of the experiments) at 72h, 48h, and 24h prior to blood 
draw or surgery. Animals were further divided into non-SBI or SBI groups; SBI 
animals underwent craniotomy and a partial right frontal lobe resection 1mm 
above the horizontal line from bregma and 2mm to the right of the vertical line 
from bregma down to the skull base as previously described (Matchett, Hahn et 
al. 2006, Jadhav, Solaroglu et al. 2007). In Cv-PC+MMP-I animals, Cv (3.7 
mg/kg) was incubated with Marimastat (3.7 mg/kg, Sigma) and AG-3340 (3.7 
mg/kg, Sigma) for 30 min at 37°C prior to subcutaneous injection, as previously 
described (Gutierrez, Leon et al. 1998, Howes, Theakston et al. 2007). 
Fibrinogen-treatment animals received one dose of fibrinogen (15 mg/1.5 ml, 
Sigma) 15 min before surgery. Blood draws on animals in the SBI groups were 
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performed 6 h after surgery. Coagulation studies performed by a blinded operator 
using standard human testing included aPTT, PT, INR, D-dimers, soluble fibrin, 
fibrinogen and fibrin split products (FSP). Previous studies have established 
normal ranges in rats using human test methods (Takahashi, Hirai et al. 2011).   
 
Spectrophotometric Assay of Hemoglobin 
At 24 h after SBI, the animals were placed under deep anesthesia and 
transcardially perfused with 0.1 M PBS until the outflowing fluid from the right 
atrium became colorless. The brain was removed and dissected into left and right 
hemispheres. Hematoma volume was quantified by spectrophotometric assay of 
brain hemoglobin content as described previously (Hu, Ma et al. 2011). A 
standard curve was obtained by adding incremental volumes of homologous 
blood to perfused brain tissue of naïve animals. The hemispheric samples were 
then homogenized and sonicated in distilled water followed by a 30-minute 
centrifugation (13,000 g at 4°C); Drabkin reagent (1.6 mL; Sigma) was added to 
0.4 mL supernatant aliquots and optical density was measured at 540 nm via 
spectrophotometer (Spectronix 3000; Milton-Roy). Hemoglobin measurements 
were compared with the standard curve to obtain hemorrhage volume expressed 
as µL of blood per ipsilateral hemisphere. Intraoperative hemorrhage volume was 
collected by suction throughout surgery and was added to packing material used 
for hemostasis during the procedure; distilled water was added bringing the 
volume to 50 mL for each collected hemorrhage sample. A standard curve was 
obtained by adding incremental volumes of homologous blood to distilled water 
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to create solutions of 50 mL total volume. Samples were homogenized, 
sonicated, and prepared for spectrophotometric assay as described above. 
Testing was done in duplicate. 
 
Blood Draws 
Blood was collected by cardiac puncture. The animals were anesthetized 
with isoflurane, then moved to a sacrifice table where incision was made 
extending from right upper quadrant to left upper quadrant. Once inside the 
peritoneum the diaphragm was cut out to visualize the heart and a 18-gauge 
needle was placed in the right ventricle; the first few drops of blood we discarded 
to eliminate tissue factor from the blood draw. Further blood was collected in 10-
cc syringe and rapidly transferred to the appropriate collection tubes, gently 
mixed by ten inversions, and delivered to the appropriate laboratories for 
subsequent testing. 
Specimens destined for soluble fibrin, PT/INR, aPTT, fibrinogen and D-
Dimer testing were anticoagulated in a mixing ratio of one part citrate to nine 
parts blood using Greiner Bio-One Vacuette® tubes (Part No. 454334) containing 
3.2% (0.109M) Sodium Citrate Solution. Specimens for Fibrin Split Product (FSP) 
testing were added to Thrombo-Wellcotest™ Collection Tubes (Part No. 
R30853001) containing soya bean trypsin inhibitor (approximately 3600 NF 
units/tube) and C. atrox venom (>10µg/tube) for the collection of 2mL whole 
blood. 
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Soluble Fibrin Analysis 
All samples were maintained at 37°C from draw through testing. The 
testing was as described by Hay et. al., but modified slightly since the 
appearance of endpoints in rat blood were somewhat atypical as compared to 
human endpoints (Hay and Bull 2002). The modification (reading endpoints using 
90 µL plasma rather than the usual 150 µL whole blood) clarified the endpoints 
and allowed for comparison between rats and treatment groups. However, the 
results cannot be compared to usual human values.   
 
PT/INR/APTT/Fibrinogen Analysis 
Blood was centrifuged at 7200 RPM (4440 x g) for 2 min using the 
STATSpin Express 3 to obtain plasma for testing. Testing was performed using a 
BCS® XP System (Siemens Healthcare, Munich, Germany). The PT/INR were 
performed using Dade® Innovin® reagent. The aPTT was performed using 
Dade® Actin® FSL reagent and 0.025M CaCl2. Fibrinogen assays were 
performed using Dade® Thrombin Reagent, Dade® Fibrinogen Standard and 
Dade® Owren’s Veronal Buffer. 
 
D-Dimer Analysis 
Blood was centrifuged at 7200 RPM (4440 x g) for 2 min using the 
STATSpin Express 3 to obtain plasma for testing. Testing was performed using 
the Cobas® 8000 modular analyzer (Roche Diagnostics, Indianapolis, IN). The 
method is based on latex particles coated with monoclonal anti-human D-Dimer 
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antibodies (mouse) to which addition of a sample containing D-Dimer increases 
turbidity leading to changes in absorbance over time. 
 
Fibrin Split Products Analysis 
Blood was centrifuged at 7200 RPM (4440xg) for 2 min using the 
STATSpin Express 3 to obtain serum for testing. Testing was performed using 
the Thrombo-Wellcotest™ Rapid Latex FDP Assay. The kit test utilizes latex 
particles, which have been coated with rabbit antibodies to fibrin fragments. The 
approximate concentration is determined from agglutination observed on serial 
specimen dilutions. 
 
HPLC 
Lyophilized crude venom was diluted to a concentration of 6 mg/mL in 
Buffer A (0.065% TFA, 2% acetonitrile in Nanopure water) and centrifuged at 
15,000 g for 10 min. The supernatant (100 µL) was fractionated on an 
ÄKTAmicro high-pressure liquid chromatography (HPLC) system (GE Healthcare 
Life Sciences, Piscataway, NJ, USA) fitted with two reversed-phase (RP) 
columns (SOURCE 5RPC ST polystyrene/divinyl benzene, 4.6 150 mm; GE 
Healthcare) run in series at a flow rate of 0.5 mL/min, using a linear gradient of 
0–100% Buffer B (0.05% TFA, 80% acetonitrile in Nanopure water) over 40 
column volumes. Protein elution was monitored at 214 nm using Unicorn 5.0 (GE 
Healthcare Lifesciences) software, and fractions were collected manually.  
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LC-MS 
Each fraction was subjected to reduction and alkylation prior to enzymatic 
digestion using dithiothreitol and iodoacetamide, respectively, following the 
protocol outlined by Matsudaira (1993). Proteins were then digested with 
proteomics-grade porcine pancreatic trypsin (Sigma-Aldrich, St. Louis, MO, 
USA). We desalted samples using C18 ZipTips (EMD Millipore, Billerica, MA, 
USA) according to the manufacturer’s protocol. We analyzed the desalted tryptic 
peptides with a ThermoFinnigan LCQ Deca XP spectrometer (ThermoFinnigan, 
Waltham, MA, USA) equipped with a PicoView 500 nanospray apparatus using 
Xcalibur software (ver. 1.3; ThermoFinnigan, Waltham, MA, USA) for instrument 
control and data acquisition. Separation was performed on a 10-cm x 75-m-i.d. 
C18 Biobasic bead column (New Objective, Woburn, MA, USA) by injecting 20-
uL samples. Mobile phase B consisted of 98% acetonitrile, 2% water, and 0.1% 
formic acid. The gradient program was: 0% B at 0.18 mL/min for 7.5 min; 0% B at 
0.35 mL/min for 0.5 min; linear gradient to 20% B at 15 min at 0.35 mL/min; 
linear gradient to 75% B at 55 min at 0.3 mL/min (flow rate constant for 
remainder of program); linear gradient to 90% B at 60 min; hold at 90% B until 85 
min; linear gradient to 0% B at 90 min; hold at 0% B until 120 min. Spectra were 
acquired in positive ion mode with a scan range of 300–1500 m/z. We converted 
MS/MS data into peak list files using Extractmsn implemented in Bioworks 
(version 3.1; ThermoFinnigan) with the following parameters: peptide molecular 
weight range 300–3,500, threshold 100,000, precursor mass tolerance 1.4, 
minimum ion count 35. We conducted MS/MS database searches using Mascot 
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(licensed, version 2.2, Matrix Science, Boston, MA, USA) against the National 
Center for Biotechnology Information non-redundant (NCBInr) database within 
Chordata. A parent tolerance of 1.20 Da, fragment tolerance of 0.60 Da, and two 
missed trypsin cleavages were allowed. We specified carbamidomethylation of 
cysteine and oxidation of methionine in MASCOT as fixed and variable 
modifications, respectively. 
 
Gel Filtration Chromatography 
C. atrox venom for Cv-PC use was fractionated via size exclusion 
chromatography using a Superdex gel filtration column (HiLoad 16-/60 Superdex 
75PG, 17-1068-02, GE Healthcare) and Amersham Biosciences ÄKTAFPLC (18-
1900-26, GE Healthcare). Crude venom (4 mg/mL in 0.15 M ammonium 
bicarbonate) was injected into the column (500 mL sample) and separated in 
0.15 M ammonium bicarbonate at a flowrate of 1 mL/min. Individual fractions 
were collected manually at the local minimums of each peak (based on 
absorbance at 214 nm). All fractions collected were lyophilized and stored at -
20oC until use. The concentrations of each reconstituted sample was measured 
using the NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Scientific). 
 
Minimal Stimulation In Vitro Clotting/Platelet Testing 
Consenting normal adults donated 5 mL citrated blood (1 part citrate + 9 
parts blood) for each agent to be tested.  Blood was drawn into citrated syringes 
and mixed gently, then all air was expressed, a parafilm seal was placed over 
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luer tip.  Syringes were maintained horizontally at 37˚C for approximately 50-60 
min, allowing endothelial inhibitors to dissipate and platelet function to reach a 
stable phase.  During this stable phase, multiple tests could be performed and 
the results compared. 
Baseline platelet testing was done in duplicate at 37˚C as follows. Pre-
warmed reaction tubes [containing 1 mg Celite 270 (Manville Products, Denver, 
CO 80217), 450 µL 0.0055M isotonic CaCl2 and 25-35 solid glass beads, 0.5mm 
(#030001, Propper Manuf Co, NY) were pre-mixed. To this 3 drops (~150 µL) of 
well-mixed blood were added and time to completion of the clumping, sticking 
and clotting visual endpoints were measured on the Hemostasis Mechanism 
Analyzer (Boehringer Laboratories, Norristown, PA).  Endpoints were identified 
as follows: Clumping was noted when platelets adhered to each other and to the 
celite, forming visible clumps approximately the same size as the glass beads.  
Sticking was noted when platelet/celite clumps “stuck” to the walls of the cuvette 
and were carried around as the tube rotated.  Clotting was identified when the 
majority of the beads were pulled towards the left side of the rotating tube and 
carried around out of sight. 
When done with baseline testing and any necessary repeats, the blood 
level in each syringe was adjusted to exactly 3 mL in preparation for testing of 
the various venom concentrations.  After remixing, 10 µL of the venom under test 
was carefully added midway in the column of 3 mL whole blood using a 
Drummond pipette.  After exactly 30 seconds, the sample was remixed and 
testing was performed as described above.  Testing was repeated periodically 
	  81 
over ~20 minutes to monitor changes in platelet and clotting function after 
exposure to the venom.    
 
Statistical Analysis 
All values are mean ± SEM. GraphPad Prism software was used for 
statistical analysis. As specified in each figure legend, 1-way ANOVA, with 
Tukey’s comparisons, was used to determine differences among 3 or more. A P 
value <0.05 was considered significant. 
 
Study Approval 
All animal husbandry and procedures were approved by the Institutional 
Animal Care and Use Committee. The study protocol was approved by the 
Institutional Review Board at Loma Linda University. 
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CHAPTER FIVE 
CONCLUSIONS 
Summary of Findings 
Our studies examined the potential of Cv-PC in preventing SBI. Cv-PC 
reduced postoperative brain edema and improved neurological function in 
animals undergoing SBI. Cv-PC suppressed the over-expression of COX-2 
following SBI. Evaluation of COX-2 inhibition during Cv-PC demonstrated 
reversal of Cv-PC beneficial effects on edema and neurological function.  
Cv-PC was also observed to reduce both intraoperative hemorrhage and 
postoperative hematoma by over 30% in SBI animals. Cv-PC generated FSPs 
and increased plasma fibrinogen. While hemostasis was improved, Cv-PC did 
not cause clinically significant changes in PT, INR, PTT, D-Dimer, or soluble 
fibrin suggestive of a thrombotic state. MMP-inhibition abolished the improved 
coagulation by Cv-PC. Furthermore, venom fractions containing SVMPs 
maintained the ability to reduce hemorrhage by PC. 
From our data, we can conclude that 1) Cv-PC reduces brain edema and 
neurological deficits by downregulating the PLA2/COX-2 pathway; 2) Cv-PC 
increases plasma fibrinogen and decreases SBI-induced intraoperative 
hemorrhage and postoperative hematoma; 3) Cv-PC-induced increase in plasma 
fibrinogen is mediated by SVMPs; 4) Assessment of coagulation parameters 
suggest that Cv-PC does not cause a hypercoagulable, thrombotic state. 
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Clinical Implications 
 Relatively, little research has focused on understanding SBI’s 
pathophysiology. The administration of nonspecific postoperative care has been 
the mainstay of treatment for neurosurgical patients (Bruder and Ravussin 1999, 
Hellwig, Bertalanffy et al. 2003). With the rising costs of healthcare, preventive 
measures grow increasingly relevant to medical practice. Even neurosurgical 
patients without life-threatening complications must be monitored closely in the 
critical care unit (Bruder and Ravussin 1999). The prevention of brain edema in 
neurosurgical patients would not only improve individual patient outcomes but 
could also shorten hospital stays, ultimately cutting perioperative costs. 
Reduction of perioperative hemorrhage has broader applications that extend 
beyond the field of neurosurgery. Over 200 million major elective surgeries are 
performed worldwide per year (Weiser, Regenbogen et al. 2008) and up to an 
estimated $6.03 million is spent annually per hospital on blood and transfusion-
related care for surgical patients (Shander, Hofmann et al. 2010). Cv-PC has 
demonstrated its ability to reduce both edema and perioperative hemorrhage, 
making it a promising therapy to improve patient outcome and simplify 
perioperative care. Further studies are needed to isolated and characterize 
Crotalus venom components and to assess the translational viability of Cv-PC.  
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